The company held the first half of the board of directors, the board of supervisors
Release time:
2020-07-22
company held the first half of the board of directors and the board of supervisors
semi-annual performance reached a record high
news 8# November 29 , the group company held the 10th board of directors 11 meeting by means of communication, deliberated and passed the "Jianfeng Group 2019 Semi-Annual Report", "On the company's internal control system amendment" and other proposals.
In the first half of the year, the company focused on the general work policy of "innovation and reform, integration and improvement, scientific layout, and steady development " , and focused on the optimization of economic structure and industrial upgrading. Opportunities, continuous internal resource integration, improvement of internal management system, and improvement of enterprise operation efficiency. In the first half of 2019 , the company realized total operating income of 16.86 .9 billion yuan, up 12.17% year-on-year, net profit attributable to owners of the parent company 4.76 .3 billion yuan, up 57.55% year-on-year, and the semi-annual operating performance reached a record high. As of the end of 2019 6 , the company's total assets were 53.83 .1 billion yuan, up 9.82 from the beginning of the year ; Net assets were 38.17 .5 billion yuan, up 10.64 from the beginning of the year .
In the first half of the year, the company made a new breakthrough in the expansion of cement business. The group company completed the acquisition of 100% equity of Guizhou huangpinggu longmingchuan cement co., ltd. and continued to invest in the construction of its new dry cement production line with a daily production of 4500 tons of cement clinker (with waste heat power generation); Yunnan Jianfeng invested ,500 yuan to participate in the establishment of Yunnan Jianfeng Da Zhan Cement Co., Ltd, the company plans to build a cement clinker production line in Mengla County, Xishuangbanna Dai Autonomous Prefecture in accordance with relevant national policies. The company's cement subsidiaries continue to carry out in-depth "three down three improve " activities, steadily implement standardized management, while strictly controlling production costs, and continuously improve labor productivity. Daye Peak, in accordance with the spirit of the Group's standardization year, has implemented standardization of production site management and has achieved good results. Comprehensive treatment of cement packaging dust, hydraulic system of limestone stacker, cement cooling commissioning and other technical renovation projects have been carried out in an orderly manner, all of which have reached good expectations. Yunnan Jianfeng timely grasps the price changes of related products of upstream suppliers through various channels, and strictly controls the procurement cost of raw materials. Concentrate on the development of market share in the core region as a key work, constantly explore and formulate sales strategies suitable for the regional market, effectively improve the market popularity and share of Jianfeng Cement, and achieve the best business performance since it was put into production.
Jianfeng Pharmaceutical continued to increase investment in drug research and development and obtained the Drug Registration Approval for Olopatadine Hydrochloride Eye Drops. In the face of changes in the pharmaceutical sales environment, Spike Pharmaceuticals has integrated its pharmaceutical business and pharmaceutical retail, and strived to extend and expand its third-end market share. Accelerate the consistency evaluation of related drugs, and lay a good foundation for the next step to participate in the centralized procurement of drugs. Jianfeng Pharmaceutical and its subsidiaries continue to increase investment in safety and environmental protection, improve and upgrade various safeguards, and improve the level of automatic control of equipment and facilities; adhere to prevention, improve safety management and three waste treatment capabilities, and effectively reduce environmental protection and safety Production risk. In the first half of the year, Jianfeng Pharmaceutical and its subsidiaries made new progress in a number of technological innovations and engineering constructions. Jianfeng Pharmaceutical's international project of annual production of 20 .7 billion solid preparations has obtained EIA approval and completed civil engineering and bidding for some equipment. Shanghai Beika Drug Approval R & D Laboratory Renovation Project has entered the stage of equipment installation and commissioning. A number of technological transformation projects in Anhui Beika have been carried out in an orderly manner, environmental protection transformation projects such as waste gas (RTO ) and sewage treatment have been put into operation, and the annual output of 1500 tons of acetamiprid powder in pesticide preparation workshop has entered the trial production stage. The laboratory renovation of GMP of Anhui Zhongwang Small Molecule Targeted Drug Research Institute has been basically completed, and the second phase technical renovation project of GMP workshop, including common drugs and small molecule targeted antitumor drugs, has obtained government approval.
The production and operation activities of other business segments of the company are carried out in a standardized and orderly manner.
On the same day, the company also held the rd meeting of the 9th Board of Supervisors and reviewed and approved the relevant report. (Yu fruit)
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page